Skip to main content

Table 1 Patient characteristics

From: Contrast-enhanced [18 F] fluorodeoxyglucose-positron emission tomography/computed tomography in clinical oncology: tumor-, site-, and question-based comparison with standard positron emission tomography/computed tomography

  Whole patient group Histopathological confirmation
(n = 202) (n = 73)
Age (years) 61.9 ± 14.9 54.2 ± 17.3
Gender (M/F) 120/82 43/30
Tumor type a,b   
Lung cancer 38 30
Head and neck cancer 22 14
Gastrointestinal cancerc 31 7
Breast cancer 21 4
Lymphoma 36 9
Melanoma 19 2
Multiple melanoma 15 5
Otherd 18 2
Clinical question b   
Diagnosis 22 10
Staging 20 11
Restaginge 33 18
Response to chemotherapy 58 6
Response to radiotherapy 18 6
Post-surgery evaluation 11 0
Surveillance 40 22
  1. Values are mean ± standard deviation.
  2. aTwo patients were not affected by any oncologic disease after histologic confirmation.
  3. bTumor type and clinical questions correspond to the groups submitted to the tumor-based and question-based analyses.
  4. cIncluding esophageal, gastric, and colorectal cancer.
  5. dGynecologic malignancy (n = 8), testicular cancer (n = 2), sarcoma (n = 3), low-differentiated neuroendocrine carcinoma (n = 4), thymoma (n = 1).
  6. eSuspected relapse or patients with potentially resectable metastatic disease.